Detalhe da pesquisa
1.
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Cell
; 171(4): 934-949.e16, 2017 Nov 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29033130
2.
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
Lancet Oncol
; 22(1): 118-131, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33387490
3.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N Engl J Med
; 372(21): 2006-17, 2015 May 21.
Artigo
Inglês
| MEDLINE | ID: mdl-25891304
4.
Nivolumab in previously untreated melanoma without BRAF mutation.
N Engl J Med
; 372(4): 320-30, 2015 Jan 22.
Artigo
Inglês
| MEDLINE | ID: mdl-25399552
5.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med
; 373(1): 23-34, 2015 Jul 02.
Artigo
Inglês
| MEDLINE | ID: mdl-26027431
6.
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Lancet Oncol
; 17(7): 943-955, 2016 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-27269740
7.
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncol
; 17(11): 1558-1568, 2016 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-27622997
8.
Nivolumab plus ipilimumab in advanced melanoma.
N Engl J Med
; 369(2): 122-33, 2013 Jul 11.
Artigo
Inglês
| MEDLINE | ID: mdl-23724867
9.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 16(4): 375-84, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25795410
10.
Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of ßIII-tubulin expression as a predictive marker.
Oncologist
; 18(7): 787-94, 2013.
Artigo
Inglês
| MEDLINE | ID: mdl-23853246
11.
Metastasis gets site specific.
Cancer Cell
; 8(2): 93-5, 2005 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-16098461
12.
Hallmarks of Resistance to Immune-Checkpoint Inhibitors.
Cancer Immunol Res
; 10(4): 372-383, 2022 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35362046
13.
Altered gene and protein expression by Nm23-H1 in metastasis suppression.
Mol Cell Biochem
; 329(1-2): 141-8, 2009 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-19415462
14.
Clinical-translational approaches to the Nm23-H1 metastasis suppressor.
Clin Cancer Res
; 14(16): 5006-12, 2008 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-18698018
15.
Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.
Cancer Res
; 67(15): 7238-46, 2007 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-17671192
16.
Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma.
Cancer Immunol Res
; 7(3): 458-465, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30635271
17.
Metabolomic adaptations and correlates of survival to immune checkpoint blockade.
Nat Commun
; 10(1): 4346, 2019 09 25.
Artigo
Inglês
| MEDLINE | ID: mdl-31554815
18.
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Clin Cancer Res
; 25(7): 2174-2184, 2019 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30670497
19.
Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth.
Clin Exp Metastasis
; 25(2): 131-8, 2008.
Artigo
Inglês
| MEDLINE | ID: mdl-18058029
20.
The role of metastasis suppressor genes in metastatic dormancy.
APMIS
; 116(7-8): 586-601, 2008.
Artigo
Inglês
| MEDLINE | ID: mdl-18834404